LENZ
NASDAQ HealthcareLENZ Therapeutics, Inc. - Common Stock
Biotechnology
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
๐ Market Data
| Price | $8.88 |
|---|---|
| Volume | 847,996 |
| Market Cap | 278.43M |
| Beta | 2.290 |
| RSI (14-Day) | 40.5 |
| 200-Day MA | $24.62 |
| 50-Day MA | $10.63 |
| 52-Week High | $50.40 |
| 52-Week Low | $8.25 |
| Forward P/E | -2.93 |
| Price / Book | 0.98 |
๐ฏ Investment Strategy Scores
LENZ scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (99/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ฐ Dividend Daddy (3/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find LENZ in your text
Paste any article, transcript, or post โ the tool will extract LENZ and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.